82586-52-5

• 常用中文名：盐酸莫昔普利
• 常用英文名：Moexipril HCl
• CAS号：82586-52-5
• 分子式：C₂₇H₃₅ClN₂O₇
• 分子量：535.03
• 相关类别： 生物化工 抑制剂 内分泌及激素(Endocrinology & Hormones) RAAS 抑制剂
• 发布时间：2018-02-17 08:00:00
• 更新时间：2026-07-01 16:25:13
• Moexipril盐酸盐是口服活性的不含巯基的血管紧张素转化酶抑制剂,可作用于高血压和充血性心力衰竭。

名称

• 中文名: 盐酸莫昔普利
• 英文名: (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid,hydrochloride
• 中文别名: 莫昔普利盐酸盐; (3S)-2-[(2S)-2-[[(1S)-1-(乙氧羰基)-3-苯基丙基]氨基]-1-氧代丙基]-1,2,3,4-四氢-6,7-二甲氧基-3-异喹啉羧酸盐酸盐; 盐酸莫昔普利 标准品; (3S)-2-[(2S)-2-[[(1S)-1-(ETHOXYCBONYL)-3-PHENYLPROPYL]AMINO]-1-OXOPROPYL]-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-3-ISOQUINOLINECBOXYLIC ACID 盐酸盐; (S)-2-((S)-2-(((S)-1-乙氧基-1-氧代-4-苯基丁烷-2-基)氨基)丙酰基)-6,7-二甲氧基-1,2,3,4-四氢异喹啉-3-羧酸盐酸盐; 2-[2-[(1-乙氧基甲酰-3-苯基丙基)氨基]丙酰基]-6,7-二甲氧基-3,4-二氢-1H-异喹啉-3-羧酸盐酸盐; 莫昔普利盐酸; 莫西普利盐酸盐; MOEXIPRIL 盐酸盐; 莫昔普利盐酸盐,10 MM DMSO 溶液
• 英文别名: 2-[(2S)-2-[[(1S)-1-(Ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylicacidhydrochloride; Moexipril hydrochloride, >=; SPM-925; (S)-2-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-cboxylic acid hydrochloride; (3S)-2-[(2S)-2-[[(1S)-1-Ethoxycbonyl-3-Phenyl-Propyl]Amino]Propanoyl]-6,7-Dimethoxy-3,4-Dihydro-1H-Isoquinoline-3-Cboxylic Acid Hydrochloride; Moexipril HydrochlorideQ: What is Moexipril Hydrochloride Q: What is the CAS Number of Moexipril Hydrochloride Q: What is the storage condition of Moexipril Hydrochloride Q: What e the applications of Moexipril Hydrochloride; Moexipril HCl (RS-10085); (3S)-2-[(2S)-2-[[(1S)-1-cbethoxy-3-phenyl-propyl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride; Fempress; UNII-Q1UMG3UH45; (3S)- 2-[(2S)-2-[[(1S)-1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylic acid,hydrochloride (1:1); Moexipril HCl - Bio-X; SPM 925; Moexipril Hydrochloride; orally active,Apoptosis,Ischemic brain injury,inhibit,hatic disease,RS10085,Angiotensin-converting Enzyme (ACE),hydrochlorothiazide,essential hypertension,Moexipril hydrochloride,antihypertensive,moexiprilat,angiotensin II,cdiovasculdisease,RS 10085,Inhibitor,hypertension,Moexipril; 2-[2-[[1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylic acid, hydrochloride; (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan -2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetr ahydroisoquinoline-3-cboxylic acid hydrochloride; RS-10085-197; MOEXIPRIL HYDROCHLORIDE //BP; Moexipril (hydrochloride); Moexipril hydrochloride, 10 mM in DMSO; Moexipril HCL; 3-Isoquinolinecboxylicacid,2-[(2S)-2-[[(1S)-1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-,hydrochloride (1:1), (3S); (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenyl-butan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride; Univasc; (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylic Acid Hydrochloride; UNIVASC;RS10085;RS 10085;RS-10085; RS-10085; CI-925; MOEXIPRIL HYDROCHLORIDE; (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycbonyl)-3-phenyl-d5-propyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylic Acid Hydrochloride; Perdix; Uniretic

物化性质

• 沸点: 709.3ºC at 760 mmHg
• 熔点: 141-161ºC
• 分子式: C₂₇H₃₅ClN₂O₇
• 分子量: 535.03
• 闪点: 382.8ºC
• PSA: 114.40000
• LogP: 3.71510
• 外观性状: 一种细白色至灰白色粉末
• 储存条件: 2-8°C

生物活性

• 描述: Moexipril盐酸盐是口服活性的不含巯基的血管紧张素转化酶抑制剂,可作用于高血压和充血性心力衰竭。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 血管紧张素转换酶(ACE)
  研究领域 >> 心血管疾病
• 参考文献:

  [1]. Chrysant, S.G. and G.S. Chrysant, Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol, 2004. 44(8): p. 827-36.

  [2]. Edling, O., et al., Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther, 1995. 275(2): p. 854-63.

  [3]. Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41(3): p. 207-24.

安全

• 符号: GHS09
• 信号词: Warning
• 危害声明: H400
• 警示性声明: P273
• 个人防护装备: Eyeshields;Gloves
• 危害码 (欧洲): N:Dangerous for the environment
• 风险声明 (欧洲): R50
• 安全声明 (欧洲): 60
• 危险品运输编码: UN 3077
• RTECS号: NW7174500

合成路线

82586-51-4 ~88% 82586-52-5

文献：Klutchko; Blankley; Fleming; Hinkley; Werner; Nordin; Holmes; Hoefle; Cohen; Essenburg Journal of Medicinal Chemistry, 1986 , vol. 29, # 10 p. 1953 - 1961

上下游产品

上游产品  1
82586-51-4
下游产品  2
103775-14-0 103733-51-3